Shares edged up modestly by 1.8% following Q2 results as investors took note of regulatory progress and commercial developments, though the market reaction signals no significant positive surprise or setback.
Nano Nuclear reported strong Q1 2026 progress with advancements in its KRONOS microreactor development, strategic partnerships, and financial strength bolstered by a significant capital raise.